Gene transfer vectors based on adeno-associated virus (AAV) appear promising because of their high transduction frequencies regardless of cell cycle status and ability to integrate into chromosomal DNA. We tested AAV-mediated gene transfer into a panel of human bone marrow or umbilical cord-derived CD34' hematopoietic progenitor cells, using vectors encoding several transgenes under the control of viral and cellular promoters. Gene transfer was evaluated by (1) chromosomal integration of vector sequences and (2) analysis of transgene expression. Southern hybridization and fluorescence in situ hybridization analysis of transduced CD34 genomic DNA showed the presence of integrated vector sequences in chromosomal DNA in a portion of transduced cells and showed that integrated vector sequences ECENT DEVELOPMENTS in hematopoiesis have fa-R cilitated the identification and isolation of multipotential hematopoietic stem cells,' permitting rapid progress in genetic modification of cells for therapy of a variety of pathophysiological conditions. Prospects for the repopulation of the hematopoietic system with gene-modified cells are attractive for the treatment of inherited diseaseq2 viral infect i o n~,~,~ and oncogenic processes' as well as for identification of sources of relapse of hematologic malignancies after bone marrow (BM) transplantation.6 Therefore, the ability to insert transgenes into pluripotent hematopoietic stem cells would represent a significant advance in the field of human gene therapy. Retrovirus-mediated gene transfer into hematopoietic cells has been a c c o m p l i~h e d~~~; however, efficient retrovirus-mediated gene transfer into pluripotent hematopoietic stem cells requires cytokine-induced prestimulation.' Treatment of primitive stem cells with the presently defined cytokines results in the loss of the self-renewal capacity and in lineage commitment." Thus, cytokine-facilitated gene transfer and cell preparative procedures for retrovirus-mediated gene therapy may not be ideally suited for long-term stem cell gene therapy. Additionally, retroviral vector marking of hematopoietic cells has been observed at low frequencies in large animal models and in human thus necessitating the continued search for novel vectors capable of efficient introduction of transgenes into hematopoietic stem cells.
R cilitated the identification and isolation of multipotential hematopoietic stem cells,' permitting rapid progress in genetic modification of cells for therapy of a variety of pathophysiological conditions. Prospects for the repopulation of the hematopoietic system with gene-modified cells are attractive for the treatment of inherited diseaseq2 viral infect i o n~,~,~ and oncogenic processes' as well as for identification of sources of relapse of hematologic malignancies after bone marrow (BM) transplantation.6 Therefore, the ability to insert transgenes into pluripotent hematopoietic stem cells would represent a significant advance in the field of human gene therapy. Retrovirus-mediated gene transfer into hematopoietic cells has been a c c o m p l i~h e d~~~; however, efficient retrovirus-mediated gene transfer into pluripotent hematopoietic stem cells requires cytokine-induced prestimulation.' Treatment of primitive stem cells with the presently defined cytokines results in the loss of the self-renewal capacity and in lineage commitment." Thus, cytokine-facilitated gene transfer and cell preparative procedures for retrovirus-mediated gene therapy may not be ideally suited for long-term stem cell gene therapy. Additionally, retroviral vector marking of hematopoietic cells has been observed at low frequencies in large animal models and in human thus necessitating the continued search for novel vectors capable of efficient introduction of transgenes into hematopoietic stem cells.
We have recently used viral vectors based on the non- pathogenic human parvovirus, adeno-associated virus (AAV), to efficiently confer intracellular resistance to human immunodeficiency virus type-1 (HIV-1) and herpes simplex virus type-1 (HSV-1).3,'3 AAV is a single-stranded, replication-defective DNA virus with a 4.7-kb genome with palindromic inverted terminal repeats (ITRs).I4 Coinfection with a helper virus, such as herpes simplex virus or adenovirus, is necessary for productive infe~ti0n.I~ In the absence of helper virus coinfection, wild-type AAV integrates in a sitespecific fashion via the ITRs into AAVS 1, located at the qter13.3 of the human chromosome 19." Latent wild-type AAV infections have been stably maintained in tissue culture for over 100 serial passages in the absence of selective pressure, attesting to the stability of AAV genomic integration." AAV vectors have a wide host range, can encode multiple, independently transcribed genes and, similar to the wildtype virus, integrate into host chromosomal Although AAV vectors do not appear to integrate into the same chromosomal site (AAVS1) as wild-type AAV, little is known regarding the mechanism of vector integration.
To further evaluate the utility of AAV vectors for gene therapy of HIV infection? and oncogenesis,2" we are investigating the biology of AAV-mediated gene transfer into human hematopoietic progenitor cells. We have previously shown that AAV vectors do not require active cell division at the time of vector exposure to mediate stable and efficient gene transfer. 21 These findings were recently extended to primary cells by studies that reported AAV vector transduction of nondividing respiratory epithelial cells" and postmitotic neurons of the brain.23 AAV transduction of transformed cells arrested in cell division by mitotic inhibitors such as nocodazole and methotrexate has also been recently reported. 24 These results suggest that AAV vector transduction of quiescent cell populations, such as pluripotent hematopoietic stem cells, may be feasible even in the absence of cytokine prestimulation.
Because the long-term intracellular stability of transgene sequences is critical for hematopoietic progenitorlstem cell gene therapy, it is important to assess chromosomal integration potential of AAV vectors in primary human CD34 cells. Because PCR-based analyses of AAV transduction may be confounded by the survival of unintegrated episomal vector genomes, we reasoned that a direct assessment of vector integration into primary chromosomal DNA was imperative for the evaluation of AAV vectors for long-term human stem cell gene therapy.
In this study, we investigated the capacity of AAV vectors to transfer genes into human BM or umbilical cord bloodderived CD34+ hematopoietic progenitor cells both by transgene expression and vector integration into chromosomal DNA. Transduction of a panel of CD34 cells was tested both in suspension cultures and colony-forming assays, using a series of AAV vectors. Gene transfer and expression were observed in a significant fraction of CD34 cells and were not dependent on cytokine prestimulation of target cells. Both Southem and fluorescence in situ hybridization (FISH) analyses showed integration of vector sequences into chromosomal DNA in CD34 cells derived from different donors, suggesting that AAV-mediated gene transfer could result in the stable genetic modification of cells. These findings may provide the basis for the use of AAV vectors for the safe and efficient gene transfer into primitive hematopoietic progenitor cells.
MATERIALS AND METHODS
Plasmids and vectors. All AAV vectors used in this study were derived from the previously described base vector, CWRSV, which contains bases 1-189 and 4045-4680 from wild-type AAV2, including the 5' and 3' ITRs and the endogenous AAV2 polyadenylation signal. CWRAP was constructed by inserting the thermostable human placental alkaline phosphatase (PLAP) gene from PDAP'~.'" as a 1.9-kb Sal I fragment into the Sal I site of pCWRSV under Rous Sarcoma virus (RSV) long terminal repeat CTR) promoter control (Fig 1) . vCWRHlVASVN contains two transcriptional cassettes, one encodes neomycin phosphotransferase under simian virus 40 (SV40) early promoter control and the other encodes an antisense transcript complementary to HIV-I LTR sequences under RSV LTR control.? CWRHIVAPAP was derived from vCWRHIVASVN by substitution of the NeoR cassette with a cassette encoding PLAP under murine phosphoglycerate kinase (PGK-I) promoter control. CWRSP-MDR encodes the human multidrug resistance gene (MDRI) under RSV LTR promoter control and will be described in detail elsewhere." BM samples were obtained from healthy donors for allogeneic transplant recipients by informed consent and using a City of Hope Institutional Review Board-approved protocol. Discard human umbilical cord blood samples were obtained from the Department of Obstetrics and Gynecology at Huntington Memorial Hospital (Pasadena, CA). Mononuclear cells were separated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) centrifugation, and CD34 cells were isolated by either incubation with HPCA-I, a murine anti-CD34 antibody (Becton Dickinson, San Jose, CA), followed by selection with sheep antimouse Ig-coated immunomagnetic beads (Dynal, Great Neck, NY) or by panning on soybean agglutinin-coated flasks followed by selection on anti-CD34-coated flasks (Applied Immune Sciences, Santa Clara, CA) as per manufacturer's directions. CD34 purity was 70% to 95% as determined by direct immunofluorescence with fluorescein isothiocyanatetonjugated HPCA-2. Unless otherwise noted, cells were cultured in RPMI 1640 or Iscove's modified Dulbecco's medium containing 20% heatinactivated fetal calf serum, 2 mmol/L glutamine, 100 UlmL penicillin, and 100 mg/mL streptomycin with specific cytokines at 37°C in humidified 5% COz. Interleukin For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From tive controls were prepared by processing helper virus-infected 293 cells transfected with vector plasmid in the absence of AAV rep and cap genes. Cells were lysed and processed exactly as described above for vector. All cell lines were tested and found to be free of mycoplasma contamination.
Transductions. CD34-enriched mononuclear cells were transduced with vector stocks at MOIs ranging from 0.2 to 3 using vector volumes ranging from 10 to 200 pL, depending on the vector titer and the particular experiment. Transductions were performed immediately after isolation and at culture initiation, except where noted otherwise. Transductions were performed by the addition of sonicated (30 seconds at full power) and centrifuged (30 seconds at 12,OOOg) vector directly to the cells in 2 to 3 mL of culture medium (described above) in a single well or in replicates in 12-well plates. The total volume of vector added never exceeded 5% of the final culture volume. Immediately after transduction, cells were placed in a humidified incubator at 37°C in 5% CO,. Where indicated, cells were washed 3 times in phosphate-buffered saline 24 hours after the addition of vector.
Transduced and untransduced CD34 cells were plated at 5,000 to 10,000 cells per well in 12-well plates with 2 mL Methocult medium (Stem Cell Technologies, Vancouver, BC) 2 to 7 days after transduction. In selected experiments, G418 was added to a final concentration of 1,OOO bg/mL of active drug. Colonies containing greater than 50 cells were scored 14 to 17 days after plating in methylcellulose.
Alkaline phosphatase assays. Cellular expression of the thermostable PLAP transgene was assayed as previously described."' Stained cells were enumerated microscopically. Colonies arising from CD34 cells were similarly stained in situ for PLAP transgene expression by gently overlaying with appropriate staining solutions.'" DNA analysis. CD34 cells were transduced with either vCWRHIVAPAP or vCWRSP-MDR at an MOI of 2. Cells were washed 24 hours after transduction and placed in liquid culture as described above. Genomic DNA was extracted 7 days after transduction by standard methods33 and digested with Dpn I, an enzyme that cleaves bacterially methylated DNA, to remove residual plasmid DNA. Approximately 3 to 10 pg of DNA was digested with either Sal I (single cutter) or BamHI (double cutter). The DNA was resolved in a 0.9% agarose gel in Tris-acetate-EDTA buffer and transferred to nitrocellulose. Blots were hybridized with high specific activity, 32P-labeled DNA probes generated either by random primer labeling of vector-specific fragments or by PCR amplification of vector sequences.
FISH analysis. CD34 cells isolated from human umbilical cord blood were transduced with vCWRHIVASVN at an MOI of 0.2 and cultured in either RPMI or Iscove's modified Dulbecco's medium containing 20% heat-inactivated fetal calf serum, 2 mmol/L glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, 10 ng/mL IL-3 (R & D Systems), 5 ng/mL IL-6 (R & D Systems), and 1 ng/mL stem cell factor (R & D Systems). Forty-eight hours before collection of cells for cytogenetic preparation, the cytokine concentration was increased to 10 ng/mL L -3 , 10 ng/mL IL-6, and 10 ng/mL stem cell factor to obtain sufficient cells in metaphase for analysis. Twenty-four hours before cells were harvested, fresh media containing the higher concentration of cytokines and colcimide at a concentration of 0.025 mg/mL were added. For cells in culture for 1 week or less, colcimide treatment for 12 hours was found to be sufficient to yield maximum numbers of cells in metaphase. The extent of colcimide bloclung was determined empirically from the average doubling time of CD34 cells from cord blood (45 hours; data not shown). In cultures over 1 week old, cells were treated with colcimide for approximately half of the doubling time to optimize the number of cells that had passed through and were, subsequently.
Colony-forming assays.
blocked in metaphase. After colcimide treatment, cells were harvested and fixed, and cytogenetic preparations were made ab described in Rooney and Czepulkowski (1992).j4 A 3.6-kb Hpa ISnaBI fragment was isolated from pCWFWIVASVN and labeled with digoxygenin-deoxyuridine triphosphate by nick-translation (Boehringer Mannheim). Hybridization and washes were performed as described in the Oncor Chromosome In Situ Hybridization System Handbook." Visualization and imaging of the slides were achieved using an Oncor, Inc (Gaithersburg, MD) imaging system housed in the core cytogenetics facility at the City of Hope National Medical Center.
RESULTS

AAV-mediated gene transfer into CD34 cells.
We initially tested AAV transduction of primary BM-derived CD34 cells using vCWRAP, an AAV vector encoding the PLAP gene. Cells were transduced with vCWRAP (MOI, 0.5), a control vector, or vCWRHIVASVN3 or were left untransduced, before placement in suspension cultures in media containing IL-3 and IL-6. Figure 2A shows the frequency of PLAP-expressing cells from three donors on day 8 posttransduction. Specific transgene expression was observed in 39% to 58% of the CD34 cells with little or no background observed in either the control-transduced (vCWRHI-VASVN) or untransduced cells. Similar results were observed when cells were washed extensively 24 hours after transduction. PLAP expression above background was not detected when CD34 cells were exposed to lysates prepared from adenovirus or HSV-infected 293 cells transfected with vector plasmids in the absence of AAV rep and cap genes (data not shown). Additionally, no specific PLAP expression was observed when vector stocks were precleared with anti-AAV antibodies and immunomagenetic beads (data not shown). These results suggest that gene transfer was mediated by AAV virions and that PLAP expression in CD34 cells was specific for vector transduction.The frequency of PLAP expression observed in BM-derived CD34 cells transduced with vCWRAP closely approximated the maximal level of transduction expected at an MOI of 0.5.
Transduction of human umbilical cord blood CD34 cells with vCWRAP (MOI, 0.25 to 0.30) was tested after transduction with vector in the form of lysates or after further purification through isopycnic cesium chloride gradients. Figure  2B shows transgene expression in 16% to 32% of cells at 1 week (donors RE and SE) posttransduction. Totals of 18% and 16% of cells from donor RE showed transgene expression on transduction with crude cell lysate or cesium-purified vector, respectively. Similarly, for donor SE, 17% of CD34 cells expressed PLAP on transduction with crude lysates as compared with 32% with cesium chloride-purified vector. AAV vector transduction of cord blood CD34 cells showed a greater donor-to-donor variability than that generally observed with BM.
Integration of AAV vector sequences in CD34 hematopoietic cells. We next analyzed the fate of the vector genomes in BM CD34 cells after AAV transduction in the absence of selective pressure. Southern hybridization analyses of PCRamplified vector-specific sequences had previously shown the presence of vector sequences in high molecular weight (HMW) DNA from transduced cells (data not shown). How- ever, the possibility of amplification from either integrated or unintegrated vector sequences precluded conclusions regarding the fate of the vector in the cell. Thus, it was important to evaluate integration by hybridization analysis of restriction enzyme-digested HMW cellular DNA. CD34 cells from four donors were transduced at an MOI of 2 with either vCWRSP-MDR (donor JM) or vCWRHIVAPAP (donors DS and KS) and were washed extensively after 24 hours. Cells were harvested 7 days posttransduction for integration analysis. HIIC2 1, a 293-based G4 1 8R clonal cell line derived after transduction with vCWRHIVASVN~ (a vector identical to CWRHIVAPAP, except for a substitution of the PLAP gene with a NeoR gene), contains 1 copy of the vector geDonor SE nome per cell and served as a positive control. Genomic DNA from vCWRSP-MDR-transduced cells was digested with Sol I, which cuts once within the vector. The DNA from vCWRH1VAPAP-transduced cells was digested using either Sol I (single cutter) or BnmHI (double cutter). After electrophoresis and capillary transfer to nitrocellulose, blots of restriction-digested DNA were hybridized to probes designed to specifically identify fragments containing vectorchromosome junctions (Fig 3A) . A limited number (2 to 6) of major vector-specific bands were detected in each sample analyzed (Figs 3B-D). Of this limited set of bands, one or two usually hybridized more strongly to the probe than did the others. In each case, the HMW bands detected were 
BamHl Probe 3
For larger than those expected from free unintegrated vector or double-stranded intermediate forms. Table 1 shows the sizes of bands expected in each case from IX and 2~ episomal forms of the vector, 2X tandem integrants, and single-copy integrants, along with the sizes of the actual bands detected in the HMW portion of the radioautographs.
Sal I-digested DNA from vCWRSP-MDR-transduced (4.9 kb) cells (donor JM) showed predominant vector-specific bands of approximately 8.6 kb and 15.8 kb when probed with probe 1, expected to identify the 5' vector-chromosome junction (Fig 3B) . Because the hybridizing bands observed on the radioautograph do not match any of the expected episomal or free multimeric sizes, we conclude that they must represent junction fragments consisting of vector and chromosomal sequences.
Analysis of HMW Sal I-digested DNA from vCWRHI-VAPAP-transduced (4. BamHl Probe3 ipproximately 2.9 kb when hybridized to probe 2 (Fig 3C) . rhis probe straddles the cleavage site by 167 bp at the 5' :nd and by 251 bp at the 3' end ( Fig 3A) and should detect it least two fragments. By PCR analysis,3h we confirmed hat the Sal I site within the integrated vector sequences was iot methylated and that the restriction digest was complete :data not shown). Again, vector-specific bands detected were :omistent with integrated vector sequences. DNA from VCWRHIVAPAP-transduced cells (donor DS) was also digested with BamHI, which cleaves twice within he vector sequences, and was probed for the 3' vector-:hromosome junction with probe 3 (Fig 3C) . Two major iybridizing bands of approximately 7.6 kb and 4 kb repreienting the 3' integration junction region between vector and :hromosomal sequences were identified. In addition, faint Jands of approximately 3.4 kb and 3 kb were observed. Each iingle-copy integrant would be expected to yield vectoripecific bands greater than 185 1 bp. Because the major bands 5,175, 3,627, 3,236, 2,737, 2,315 Sizes of the predicted vector-specific bands are shown in base pairs for various configurations of AAV vector genomes. Also shown are the actual sizes of bands observed in Southern analyses of transduced CD34 cells (Fig 3) .
detected in this blot were larger than this, we concluded that they were consistent with integrated copies of AAV vector sequences.
Finally, genomic DNA was extracted from vCWRHIVA-PAP-transduced cells and digested with BamHI, from an additional donor (donor KS). Analysis of this radioautograph showed multiple bands of HMW. These bands ranged from approximately 2.3 to 7 kb in size, with predominant bands at 7 kb, 5.1 kb, and 3.6 kb. As for donor DS, our analysis showed bands greater than 1,85 1 bp, indicating integration of vector sequences. Although some BamHI bands less than 4.1 kb from either donor (DS or KS) may correspond to episomal 2X copies (Table I) , all bands greater than this 4.1-kb boundary must represent integrated junction fragments. It is also important to note that two donors transduced with the same vector, digested with the same restriction enzymes, and probed with the same probes yielded bands of different, albeit discreet, sizes. These differences are attributed to restriction site polymorphism in the chromosomal DNA.
No vector-specific bands were ever detected in untransduced CD34 and 293 cell control DNA. Furthermore, DNA from untransduced CD34 cells of the same donors were negative for wild-type AAV2 sequences by PCR analysis using wild-type AAV-specific primers. These results suggest that AAV vector transduction resulted in integration of vector sequences into chromosomal DNA in CD34 cells.
We next confirmed AAV vector integration and quantitated integration frequencies in transduced umbilical cord blood CD34 cells by FISH analysis of cytogenetically prepared chromosomes. The vCWRHIVASVN clonal cell line, HIIC21, served as a positive control (Fig 3A) . The parent cell line (293) did not hybridize to vector-specific probes (Fig 4A) . Each metaphase spread of HIIC21 showed the presence of vector-specific signal (hybridized to an Hpa I-SnaBI fragment of vCWRHI-VASVN) on each sister chromatid of a single chromosome per cell (Fig 4B) . (Fig 4C) . Approximately 3.5% positive nuclei (7 of 198) were observed in donor FG 2 weeks after transduction (Fig 4F) . As before, the untransduced CD34 cells were negative (Fig 4E) , indicating that the detected signals were specific for the vector.
Although FISH analysis is not strictly quantitative, our results suggest that a minimum of 3% of cord blood CD34 cells in metaphase had integrated vector-specific signals at the same location on both sister chromatids when transduced at an MOI of 0.2, 1 to 2 weeks posttransduction in the absence of selective pressure. Additionally, the presence of integrated transgene sequences on both sister chromatids in metaphase spreads, indicated successful replication of the integrated vector during cellular DNA synthesis. Thus, the results of the FISH data corroborate the results of the Southem analyses and show that the AAV vectors are capable of integrating into the chromosomes in a population of transduced CD34 cells.
NeoR transduction of CD34' progenitors of colony-forming cells (CFCs). We next tested whether AAV transduction resulted in gene transfer into EM-derived CD34 hematopoietic progenitor cells capable of myeloid colony formation (colony-forming unit-granulocyte-macrophage) in vitro. Cells isolated from three individuals were transduced with vCWRHIVASVN, containing the NeoR gene under control of the SV40 early promoter, at an MOI of 3. After 4 days of suspension culture without G418, cells were placed in methylcellulose either with or without G418. The concentration of G418 used, 1,000 ,ugh& (active drug), had previously been determined to be 100% lethal to CD34 progenitor cells. Figure 5A shows colony formation by transduced and untransduced cells grown in the presence of E -3 alone, GM-CSF alone, or both. The absence of colony formation by untransduced CD34 cells in the presence of G418 confirmed that an appropriate concentration of G418 was used (Fig 5A, group 4) . In contrast to untransduced cells, significant colony formation by transduced CD34 cells was observed in the presence of G418 (Fig 5A, group l transduced cells in G418 was equal to or slightly lower than that in the absence of G418. However, in the presence of both IL-3 and GM-CSF, many more colonies were obtained, a result attributed to experimental variability. The transduction efficiency of vCWRHIVASVN was calculated as the fraction of colonies derived from transduced cells in the presence of G418 relative to those in the absence of G418 (Fig 5A, groups 1 and 2) . A mean of 175 colonies in the presence of G418 (under all culture conditions tested) as compared with a mean of 155 colonies in the absence of G418 indicated near complete transduction.
To determine whether AAV transduction was deleterious to colony formation, we compared the number of colonies obtained from either transduced or untransduced cells grown in the absence of G418. No reduction in colony formation by transduced cells, (Fig 5A, groups 2 and 3) suggested that AAV transduction was not detrimental to myeloid differentiation in vitro.
To test transgene expression in the absence of selective pressure, Transduction of CD34 CFCs with vCWRAP.
we analyzed PLAP expression in colony-forming CD34 cells transduced with vCWRAP. Figure 5B shows the percentage of colonies expressing thermostable PLAP in situ in myeloid colonies derived from CD34 cells from five individuals transduced at an MOI of 0.6. Transgene expression was observed in 49% to 72% of colonies derived from vCWRAPtransduced cells. Some background PLAP activity observed in the control-transduced (vCWRHIVASVN) population was attributed to incomplete heat-inactivation of endogenous PLAP activity in colonies embedded within the methylcellulose. After background subtraction (vCWRHIVASVN transduced cells), a range of 28% to 56% of the colonies were positive for PLAP transgene expression, after transduction at an MOI of 0.6. At this MOI (0.6), transgene expression was expected in approximately 60% of the colonies.
Effect of cytokine prestimulation of CD34 cells on AAV transduction. To determine whether prestimulation of CD34 cells with cytokines was required for optimal transduction with AAV vectors, we compared gene transfer frequencies in cells transduced with vCWRAP at the time of culture initiation, before cytokine stimulation, or 48 hours after culture in the presence of IL-3, IL-6, and GM-CSF. VCWRHIVASVN-transduced and untransduced cells served as controls. Figure 6 shows transduction frequencies of 67% when cells were transduced before cytokine exposure, as compared with those of 68% when cells were transduced 48 hours after culture with cytokines. Similar frequencies of transgene-expressing cells in both treatment groups at 7 days posttransduction suggested that prestimulation of CD34 cells with cytokines was not required for optimal AAV-mediated gene transfer. Adherent cells in the cultures, including macrophages, also showed a similar frequency of PLAP-expression in both groups. Analogous results were obtained when G418R myeloid colony formation was analyzed from CD34 cells transduced with vCWRHIVASVN either before or 48 hours after cytokine stimulation (data not shown). These results suggest that cytokine prestimulation was not required for optimal AAV transduction.
DISCUSSION
This study shows that a series of AAV vectors encoding different transgenes efficiently transduced CD34' cells derived from either normal human BM or human umbilical cord hematopoietic progenitor cells obtained from 20 different donors. Transduction of CD34 cells resulted in transgene expression in a significant population of cells when analyzed 1 to 3 weeks after transduction. Additionally, evaluation by two independent methods suggests that AAV transduction resulted in integration of vector sequences into CD34 chromosomal DNA within 7 days after transduction. Finally, these studies also show that, unlike retroviral vector transduction, transduction of CD34 cells using AAV vectors does not require cytokine prestimulation.
In all cases described here, gene transfer was evident, independent of the transgene or selective pressure. Use of one vector encoding the NeoR selectable marker under the SV40 early promoter control allowed for positive selection of transduced cells. Another vector, encoding the thermostable human PLAP gene, did not confer a growth advantage on transduced cells and was used to assess gene transfer in the absence of selective pressure. Gene transfer frequencies.
as assessed by transgene expression, closely approximated that predicted by the multiplicity of transduction in all BMderived CD34 cells analyzed. Whether this transgene expression stably persists in all cells long term is currently being studied. Importantly, similar levels of transduction were observed using cesium chloride gradient-purified vector particles as compared with those observed with crude cell lysates, indicating that gene transfer was the result of intracellular expression of transgenes and not of merely the fusion of membrane-bound vesicles containing transgene products. Additionally, no transgene expression was observed when the crude vector lysates were precleared with anti-AAV antisera before transduction (data not shown). This finding shows further that transgene expression resulted from true AAV vector transduction. The detection of transgene-encoded protein and RNA previously observed with these vectors.' for extended periods after transduction was also consistent with vector transduction. For clinical applications, the ability to transfer genes efficiently into a large fraction of hematopoietic progenitor cells in the absence of drug selection is highly desirable because the long-term effects of drug selection on the fate of transduced cells in vivo is unknown. Transgene expression was observed in the majority of CD34 cells in suspension culture in populations that ranged from 70% to 95% pure CD34', suggesting that most transduced cells represented hematopoietic progenitors.
Transgene expression was observed in myeloid colonies differentiating in vitro from transduced CD34 cells, with the numbers of transduced CFCs closely approximating the maximal number expected at the multiplicity of transduction used in each experiment. Importantly, both the recombinant vector titer as well as assessment of transduction frequencies were determined by actual transgene expression. This method of titering allowed for selective quantitation of only intact vector genomes that were competent for both encapsidation and transduction. Using functional titers to calculate the multiplicity of transduction, the incidence of transgene expression was found to be directly proportional with the MOI on most cells. Equivalent levels of colony formation by both transduced and untransduced cells grown in the absence of selective pressure suggested that AAV transduction did not inhibit myeloid differentiation in vitro. Importantly, no deleterious or toxic effects of AAV transduction were observed as judged by colony number, size, and morphology. To date, we have tested AAV-mediated gene transfer into the BM and human umbilical cord-derived CD34 cells from more than 50 individuals of varying ethnic backgrounds, with significant levels of transduction being observed in most samples. These results suggest that AAV may use a relatively conserved mode of entry into human CD34 cells. However, cells from a few donors (notably, cord blood donors) showed lower transduction frequencies than expected, indicating a possible genetic or physiological basis of AAV transduction.
Equivalent levels of AAV-mediated gene transfer obFor personal use only. on August 16, 2017 . by guest www.bloodjournal.org From served when cells were transduced either before cytokine treatment or 48 hours poststimulation indicated that cytokine-mediated induction of proliferation andor differentiation was not obligatory for AAV transduction. Similar results were recently reported with cord blood CD34 cells." These findings are in concordance with recent reports from our laboratory showing that AAV-mediated transduction of cells arrested in DNA synthesis was equivalent to that of those in logarithmic growth.2' These results have several implications for the use of AAV vectors for the genetic modification of the hematopoietic system. Pluripotent hematopoietic stem cells are postulated to be quiescent, with only a limited number being in active cell cycle at any given time." To date, the only other integrating viral vector systems available for gene therapy are retrovirus-based and require active cell division for stable integration." Thus, retrovirus-mediated gene transfer into hematopoietic progenitor cells requires cytokine prestimulation. Because specific cytokines and culture conditions that maintain the totipotential characteristics of stem cells are yet to be defined, prestimulation with cytokines may pose a significant impediment to stem cell gene therapy. Cytokine-mediated activation of hematopoietic stem cells renders them accessible to retroviral transduction; however, such treatment also results in lineage commitment, thus altering the self-renewal capacity and the ultimate fate of transduced cells.'" Unlike the findings of Alexander et al,24 in which the induction of DNA damage was required for efficient AAV transduction of nondividing human diploid fibroblasts, our results and those of others indicate that transduction efficiencies ranging from 50% to 100% are observed in a reproducible fashion in unmanipulated, normal CD34 cells that have not undergone prior treatment with DNA-damaging agents. Also contrary to the findings of Halbert et a1," our results suggest that AAV vectors transduce primary human cells at high efficiencies. Recently, efficient AAV transduction of cord blood hematopoietic progenitor cells was shown by Zhou et al,*' who assayed for NeoR transgene expression and for DNA by PCR analyses. Wild-type AAV infection of nonhuman primate CD34 cells was shown by PCR analysis." AAV transduction of the Fanconi anemia complementation group C into peripheral blood CD34 cells was shown by clonogenic assays and RNA PCR analysis. 39 Miller et alz7 have also described AAV transduction of the y-globin gene into human erythroid CFCs. However, direct analyses of AAV vector integration into chromosomal DNA of primary CD34 cells from multiple donors have not yet been reported.
To carefully determine whether transgenes can be stably inherited by the progeny of genetically modified hematopoietic stem cells, evaluation of any gene transfer system must include analyses of the fate of the vector genome after cellular transduction. Because AAV is a single stranded DNA virus, the second strand must be synthesized before transgene expression?' Such double-stranded episomal copies of the AAV vector genome may be adequate for gene expression or PCR analysis but do not predict the integration status of vector genomes. Thus, transgene expression quantified by either protein or RNA analysis39 is an insufficient measure of vector integration. Similarly, previous work from our laboratory and those from othersz7 suggests that PCR-based integration analyses performed shortly after transduction with a stable DNA vector such as AAV must be interpreted with caution. To circumvent these difficulties, we chose to perform direct integration analysis of transduced cells using Southern and FISH analyses. Southern hybridization of vector-chromosome junction fragments, after restriction digests and using vector-specific probes, showed the presence of integrated sequences in CD34 chromosomal DNA. In each case, the detection of vector-specific sequences in bands larger than either unit length vector or the expected size fragments from double-stranded unintegrated vector DNA was suggestive of chromosomal integration. Integrated vector sequences were detectable within 7 days after transduction. Interestingly, a limited number of predominant vectorspecific bands was observed in transduced CD34 cells. Whether the presence of this restricted number of vectorchromosome junction fragments was caused by (1) a preferential proliferation of a few transduced clones or (2) nonrandom vector integration into a finite number of sites, possibly hot spots for recombination, is currently unclear. However, given the presence of cytokines in the medium, it is unlikely that a limited number of clones outgrew the cultures in 7 days. Thus, although wild-type free, rep-negative AAV vectors do not appear to integrate into AAVS1. the possibility of vector integration into a finite number of other sites can not yet be excluded. Additionally, the presence of extrachromosomal vector sequences in unpredicted rearranged forms cannot be ruled out. However, for such structures to be detected as predominant bands by Southern analysis, it is expected that they would have to represent a significant portion of the vector genomes, thus ruling out random rearrangements. Interestingly, our results suggest that some degree of restriction site polymorphism may occur in the chromosomal flanking sequences. The mechanism of vector integration and proteins possibly involved in this event are as yet unknown. Whether the AAV-encoded rep 78 protein, which has been implicated in site-specific AAV integration,"' also plays a role in vector integration is unclear. There are recent reports of the association of rep 78 with certain classes of AAV virion^.^^,^^ Whether such structures contribute to vector integration requires further investigation. Additionally, the analysis of vector-chromosome junction sequences may provide further insight into the mechanism of vector integration.
To directly assess AAV vector integration and differentiate between the possibilities discussed above, we performed metaphase FISH analyses of transduced cord blood cells. The results of these studies definitively confirmed integration of vector sequences into CD34 cells. In accordance with the results of the Southern analyses, integrated vector sequences were detected within 7 days after transduction in the absence of selective pressure. Because only metaphases could definitively be scored as having integrated sequences, nondividing and slowly dividing interphase cells were, by nature, excluded from analysis. Additionally, although the criterion of scoring only positive sister chromatids may represent a conservative estimate of integration frequency, it was needed to exclude episomal vector genomes. The larger population 
